



Curriculum Vitae

Personal information **Catarina Eriksson**

Work experience

1. Employer: Medical Products Agency
 - Start date: 042012
 - End date:
 - Position: Pre_clinical Assessor
 - Activities: _ Assessment of non_clinical data (i.e. pharmacological, pharmacokinetic and toxicological data in vitro and in laboratory animals) in applications for market authorisation of human (for evaluation and mitigation of human and environmental risk) and veterinary (for evaluation and mitigation of risks for public health, i.e. for users, consumers [by withdrawal periods if applicable] and the environment) medicinal products. _ Assessment of non_clinical safety data and target animal residue data in applications for establishment of maximum residue limits (MRLs) for substances to be included in veterinary medicinal products intended for food-producing animals (for evaluation and mitigation of risks for consumers). _ Scientific advice on non_clinical data for clinical trials or market authorisation of human and veterinary medicinal products. _ Assessment of withdrawal periods for veterinary medicinal license products intended for food-producing animals. _ Swedish delegate at the EMA veterinary Safety Working Party (SWP_V) from 2016. _ Respond to external questions regarding veterinary public health.
 - Country: Sweden
2. Employer: Quintiles AB
 - Start date: 112002
 - End date: 012012
 - Position: Pharmacokineticist
 - Activities: _ Development of those parts of clinical study protocols and statistical analytical plans for Phase I studies that are related to study design and pharmacokinetic (PK) and pharmacodynamic (PD) evaluation. _ Performance of PK, PD and PK/PD analyses in Phase I studies. _ Interpretation and presentation of PK/PD results in Phase I studies.
 - Country: Sweden
3. Employer: Quintiles AB
 - Start date: 041997
 - End date: 102002
 - Position: Clinical Trial Manager/Pharmacokineticist
 - Activities: _ Management and coordination of various services performed for Phase I clinical trials (including protocol development, clinical conduct, safety lab and bioanalysis, data management, PK/PD analyses, statistical analyses and reporting). _ Contact person for subcontractors and clients. _ Overall responsible for applications to the regulatory authority and ethics committees and delivery of documents and data to clients. _ PK/PD analyses and/or writing of study protocols and study reports.
 - Country: Sweden

Education and training

1. Subject: Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, The Swedish University of Agricultural Sciences
 - Start date: 021988
 - End date: 061996
 - Qualification: Ph.D. in Pharmaceutical Science, Toxicology (1995_03_03)
 - Organisation: Research within the field of toxicology with focus on studies on herbicide-induced tissue-specific toxicity in the nasal olfactory mucosa of mice and rats and possible underlying mechanisms. Techniques used included histopathology, wholebody_ and microautoradiography, liquid scintillation of tissue pieces or subcellular tissue fractions exposed to radiolabelled substance in vivo or in vitro (for quantification and characterisation of metabolic activation and covalent binding of reactive metabolites), Ames mutagenicity test and SDS_polyacrylamide_gel_electrophoresis.
 - Country: Sweden
2. Subject: Faculty of Pharmacy, Uppsala University
 - Start date: 011984
 - End date: 011988
 - Qualification: M.Sc. in Pharmacy (Pharmacist)
 - Organisation: Various subjects in pharmaceutical sciences, e.g. chemistry, physiology, pharmacology, pharmacokinetics and toxicology. Master thesis on mutagenic potential of various flavouring substances in Ames mutagenicity test.
 - Country: Sweden

Additional information

Publications

1. Brittebo, E.B., Eriksson, C. & Brandt, I. (1990) Activation and toxicity of bromobenzene in nasal tissues in mice. Archives of Toxicology, 64, 54_60.
2. Brittebo, E.B., Eriksson, C., Feil, J., Bakke & Brandt, I. (1991) Toxicity of 2,6_dichlorothiobenzamide and 2,6_dichlorobenzamide in the olfactory nasal mucosa of mice. Fundamental and Applied Toxicology, 17, 92_102.
3. Eriksson, C. & Brittebo, E.B. (1991) Metabolic activation of the herbicide dichlobenil in the olfactory mucosa. Chemo_Biological Interactions, 79, 165_177.
4. Eriksson, C. & Brittebo, E.B. (1991) Epithelial binding of 1,1,2,2_tetrachloroethane in the respiratory and upper alimentary tract. Archives of Toxicology, 65, 10_14.
5. Brittebo, E.B., Eriksson, C. & Brandt, I. (1991) Metabolic activation of halogenated

hydrocarbons in the conjunctival excretory ducts of the intraorbital lacrimal gland in mice. *Experimental Eye Research*, 52, 245_252. 6. Brandt, I., Eriksson, C. & Brittebo, E.B. (1991) Tissuespecific toxicity and metabolic activation of 2,6_dichlorobenzonitrile and 2,6_dichlorobenzamide in the olfactory nasal mucosa. *Chemosphere*, 23, 1803_1809. 7. Brittebo, E.B., Eriksson, C. & Brandt, I. (1992) Effects of glutathione_modulating agents on the covalent binding and toxicity of dichlobenil in the mouse olfactory mucosa. *Toxicology and Applied Pharmacology*, 114, 31_40. 8. Eriksson, C., Brandt, I. & Brittebo, E.B. (1992) Tissue_binding and toxicity of compounds structurally related to the herbicide dichlobenil in the mouse olfactory mucosa. *Food and Chemical Toxicology*, 30, 871_877. 9. Brittebo, E.B., Eriksson, C., Övervik, E., Gustafsson, J.Å. & Brandt, I. (1992) Tissue distribution of the food mutagen MeIQx in control and BNF_treated mice. *Pharmacology & Toxicology*, 71, 457_460. 10. Brittebo, E.B., Darnerud, P.O., Eriksson, C. & Brandt, I. (1993) Sites of covalent binding and toxicity of 1,1_dichloroethylene in mice. *Archives of Toxicology*, 67, 605_612. 11. Eriksson, C. & Brittebo, E.B. (1995) Metabolic activation of the olfactory toxicant dichlobenil in rat olfactory microsomes: Comparative studies with p_nitrophenol. *Chemico_Biological Interactions*, 94, 183_196. 12. Eriksson, C. & Brittebo, E.B. (1995) Dichlobenil in the fetal and neonatal mouse olfactory mucosa. *Toxicology*, 96, 93_104. 13. Eriksson, C., Brandt, I. & Brittebo, E.B. (1995) Effects of the herbicide chlorthiamid on the olfactory mucosa. *Toxicology Letters*, 76, 203_208. 14. Brittebo, E.B. & Eriksson, C. (1995) Taurine and carnosine in the olfactory system: Effects of the olfactory toxicant dichlobenil. *NeuroToxicology*, 16, 271_280. 15. Eriksson, C., Busk, L. & Brittebo, E.B. (1996) 3_Aminobenzamide inhibits the metabolic activation and toxicity in the olfactory mucosa. *Toxicology and Applied Pharmacology*, 136, 324_331. 16. Eriksson, C., Bergman, U., Franzén, A., Sjöblom, M. & Brittebo, E.B. (1999) Transfer of some carboxylic acids in the olfactory system following intranasal administration. *Journal of Drug Targeting*, 7, 131_142. 17. Bergström, U., Franzén, A., Eriksson, C., Lindh, C. & Brittebo, E.B. (2002) Drug targeting to the brain: Transfer of picolinic acid along the olfactory pathways. *Journal of Drug Targeting*, 10, 469_478. 18. Wemer, J., Cheng, Y.F., Nilsson, D., Reinholdsson, I., Fransson, B., Lanbeck Vallén, K., Nyman, L., Eriksson, C., Björck, S. & Schulman, S. (2006) Safety, tolerability and pharmacokinetics of NXY 059 in healthy young and elderly subjects. *Current Medical Research and Opinions*, 22, 1813_1823. 19. Appel, L., Geffen, Y., Heurling, K., Eriksson, C., Antoni, G. & Kapur, S. (2009) BL_1020, a novel antipsychotic candidate with GABA_enhancing effects: D2 receptor occupancy study in humans. *European Neuropsychopharmacology*, 12, 841_850. 20. Lister, N., Warrington, S., Boyce, M., Eriksson, C., Tamaoka, M., & Kilborn, J. (2011) Pharmacokinetics, Safety, and Tolerability of Ascending Doses of Sublingual Fentanyl, With and Without Naltrexone, in Japanese Subjects. *The Journal of Clinical Pharmacology*, 51, 1195_1204

[Projects](#)

[Memberships](#)

[Other Relevant Information](#)